Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nail Diseases | 45 | 2026 | 51 | 14.660 |
Why?
|
| Skin Neoplasms | 45 | 2026 | 411 | 11.080 |
Why?
|
| Nails | 25 | 2025 | 39 | 5.970 |
Why?
|
| Surgical Flaps | 14 | 2021 | 117 | 5.160 |
Why?
|
| Mohs Surgery | 20 | 2026 | 54 | 4.450 |
Why?
|
| Melanoma | 16 | 2025 | 335 | 4.230 |
Why?
|
| Surgical Wound | 4 | 2020 | 10 | 2.090 |
Why?
|
| Dermatologic Surgical Procedures | 8 | 2021 | 35 | 1.960 |
Why?
|
| Dermatology | 6 | 2024 | 67 | 1.880 |
Why?
|
| Papilloma | 4 | 2020 | 12 | 1.780 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2026 | 264 | 1.770 |
Why?
|
| Foot Dermatoses | 4 | 2016 | 6 | 1.710 |
Why?
|
| Fingers | 4 | 2019 | 49 | 1.560 |
Why?
|
| Toes | 6 | 2021 | 14 | 1.510 |
Why?
|
| Nails, Malformed | 2 | 2024 | 6 | 1.470 |
Why?
|
| Rhinoplasty | 3 | 2018 | 10 | 1.310 |
Why?
|
| Ganglion Cysts | 2 | 2021 | 4 | 1.250 |
Why?
|
| Humans | 90 | 2026 | 65830 | 1.240 |
Why?
|
| Onychomycosis | 3 | 2015 | 6 | 1.230 |
Why?
|
| Nose | 4 | 2016 | 27 | 1.230 |
Why?
|
| Biopsy | 14 | 2025 | 463 | 1.180 |
Why?
|
| Lip Neoplasms | 3 | 2020 | 4 | 1.090 |
Why?
|
| Nose Neoplasms | 5 | 2014 | 17 | 1.060 |
Why?
|
| Antifungal Agents | 3 | 2025 | 125 | 1.060 |
Why?
|
| Dermoscopy | 5 | 2025 | 14 | 1.050 |
Why?
|
| Anesthesia, Local | 4 | 2016 | 20 | 1.040 |
Why?
|
| Postoperative Complications | 4 | 2026 | 1336 | 0.870 |
Why?
|
| Diagnosis, Differential | 12 | 2025 | 993 | 0.860 |
Why?
|
| Cicatrix | 3 | 2020 | 62 | 0.850 |
Why?
|
| Lip | 2 | 2020 | 12 | 0.820 |
Why?
|
| Carcinoma in Situ | 3 | 2026 | 36 | 0.750 |
Why?
|
| Facial Nerve Injuries | 1 | 2021 | 4 | 0.690 |
Why?
|
| Professional Practice Gaps | 1 | 2021 | 3 | 0.690 |
Why?
|
| Facial Paralysis | 1 | 2021 | 8 | 0.690 |
Why?
|
| Nails, Ingrown | 1 | 2021 | 1 | 0.690 |
Why?
|
| Current Procedural Terminology | 1 | 2021 | 18 | 0.690 |
Why?
|
| Tubulin Modulators | 1 | 2021 | 6 | 0.690 |
Why?
|
| Lacrimal Apparatus | 1 | 2020 | 5 | 0.650 |
Why?
|
| Middle Aged | 21 | 2026 | 18498 | 0.650 |
Why?
|
| Eye Neoplasms | 1 | 2020 | 17 | 0.650 |
Why?
|
| Scalp | 3 | 2016 | 30 | 0.640 |
Why?
|
| Male | 29 | 2026 | 31403 | 0.640 |
Why?
|
| Anesthetics, Local | 3 | 2016 | 73 | 0.630 |
Why?
|
| Glomus Tumor | 1 | 2020 | 2 | 0.620 |
Why?
|
| Arteries | 1 | 2020 | 88 | 0.620 |
Why?
|
| Splints | 1 | 2019 | 6 | 0.620 |
Why?
|
| Aged | 21 | 2026 | 15145 | 0.610 |
Why?
|
| Hand Deformities, Acquired | 1 | 2019 | 2 | 0.600 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 17 | 0.600 |
Why?
|
| Lichen Planus | 3 | 2024 | 9 | 0.600 |
Why?
|
| Female | 29 | 2026 | 34420 | 0.580 |
Why?
|
| Lasers, Dye | 1 | 2018 | 6 | 0.540 |
Why?
|
| Trichophyton | 2 | 2015 | 4 | 0.540 |
Why?
|
| Forehead | 2 | 2014 | 15 | 0.530 |
Why?
|
| Lasers, Solid-State | 1 | 2018 | 19 | 0.530 |
Why?
|
| Wound Healing | 3 | 2016 | 193 | 0.520 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 502 | 0.480 |
Why?
|
| Melanosis | 2 | 2020 | 10 | 0.470 |
Why?
|
| Treatment Outcome | 9 | 2021 | 5834 | 0.470 |
Why?
|
| Triamcinolone Acetonide | 1 | 2016 | 14 | 0.470 |
Why?
|
| Drug Resistance, Multiple, Fungal | 1 | 2015 | 4 | 0.460 |
Why?
|
| Tourniquets | 2 | 2026 | 8 | 0.450 |
Why?
|
| Triazoles | 1 | 2015 | 63 | 0.440 |
Why?
|
| Fibroma | 1 | 2015 | 14 | 0.440 |
Why?
|
| Hemangioendothelioma | 1 | 2014 | 5 | 0.440 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 166 | 0.440 |
Why?
|
| Lipoma | 1 | 2014 | 17 | 0.430 |
Why?
|
| Foot Deformities | 1 | 2014 | 1 | 0.430 |
Why?
|
| Esthetics | 4 | 2020 | 20 | 0.430 |
Why?
|
| Shoes | 1 | 2014 | 13 | 0.430 |
Why?
|
| Nerve Block | 2 | 2016 | 62 | 0.430 |
Why?
|
| Thumb | 4 | 2020 | 27 | 0.430 |
Why?
|
| Lasers, Gas | 1 | 2014 | 2 | 0.430 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 32 | 0.420 |
Why?
|
| Onycholysis | 1 | 2014 | 2 | 0.420 |
Why?
|
| Betamethasone | 1 | 2014 | 6 | 0.420 |
Why?
|
| Glucocorticoids | 1 | 2016 | 190 | 0.420 |
Why?
|
| Steroids | 1 | 2014 | 56 | 0.410 |
Why?
|
| Calcitriol | 1 | 2014 | 25 | 0.410 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 24 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 711 | 0.390 |
Why?
|
| Paraneoplastic Syndromes | 2 | 2010 | 10 | 0.380 |
Why?
|
| Frozen Sections | 1 | 2012 | 11 | 0.380 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2014 | 169 | 0.380 |
Why?
|
| Adult | 12 | 2026 | 17575 | 0.380 |
Why?
|
| Aged, 80 and over | 9 | 2026 | 5681 | 0.370 |
Why?
|
| Orthopedic Procedures | 1 | 2013 | 55 | 0.360 |
Why?
|
| Retrospective Studies | 9 | 2026 | 6955 | 0.360 |
Why?
|
| Suture Techniques | 1 | 2013 | 97 | 0.360 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2500 | 0.350 |
Why?
|
| Ischemia | 1 | 2013 | 203 | 0.330 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 489 | 0.320 |
Why?
|
| Melanocytes | 2 | 2025 | 77 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2026 | 378 | 0.290 |
Why?
|
| Nevus, Blue | 1 | 2008 | 2 | 0.280 |
Why?
|
| Dermabrasion | 1 | 2008 | 1 | 0.280 |
Why?
|
| Cheilitis | 1 | 2008 | 5 | 0.280 |
Why?
|
| Precancerous Conditions | 2 | 2008 | 74 | 0.270 |
Why?
|
| Melanoma, Amelanotic | 1 | 2008 | 2 | 0.270 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 33 | 0.270 |
Why?
|
| Pigmentation Disorders | 1 | 2007 | 9 | 0.260 |
Why?
|
| Internship and Residency | 1 | 2015 | 800 | 0.260 |
Why?
|
| Skin Transplantation | 2 | 2018 | 154 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 206 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 220 | 0.250 |
Why?
|
| Clinical Competence | 2 | 2021 | 731 | 0.250 |
Why?
|
| Tinea Pedis | 1 | 2006 | 2 | 0.250 |
Why?
|
| Epidermal Cyst | 1 | 2006 | 11 | 0.250 |
Why?
|
| Hematoma | 1 | 2007 | 85 | 0.250 |
Why?
|
| Epinephrine | 3 | 2016 | 46 | 0.240 |
Why?
|
| Cheek | 2 | 2021 | 5 | 0.230 |
Why?
|
| Skin Diseases | 1 | 2006 | 82 | 0.230 |
Why?
|
| Yellow Nail Syndrome | 1 | 2025 | 1 | 0.230 |
Why?
|
| Administration, Cutaneous | 2 | 2015 | 31 | 0.230 |
Why?
|
| Plants, Medicinal | 1 | 2005 | 19 | 0.230 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 251 | 0.230 |
Why?
|
| Perioperative Care | 1 | 2026 | 89 | 0.220 |
Why?
|
| Phytotherapy | 1 | 2005 | 34 | 0.220 |
Why?
|
| Vitamin E | 1 | 2025 | 55 | 0.220 |
Why?
|
| Bibliometrics | 1 | 2004 | 35 | 0.200 |
Why?
|
| Naphthalenes | 2 | 2015 | 17 | 0.190 |
Why?
|
| Pain | 2 | 2016 | 400 | 0.190 |
Why?
|
| Injections, Intralesional | 2 | 2016 | 14 | 0.180 |
Why?
|
| Dermatologists | 1 | 2021 | 12 | 0.170 |
Why?
|
| Betacoronavirus | 2 | 2020 | 182 | 0.170 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 178 | 0.170 |
Why?
|
| Air Pollutants, Occupational | 1 | 2021 | 75 | 0.170 |
Why?
|
| Finger Joint | 1 | 2021 | 13 | 0.170 |
Why?
|
| Nasolabial Fold | 1 | 2020 | 1 | 0.160 |
Why?
|
| Mentors | 1 | 2021 | 118 | 0.160 |
Why?
|
| Consensus | 1 | 2021 | 174 | 0.160 |
Why?
|
| Administration, Oral | 2 | 2025 | 371 | 0.160 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2790 | 0.160 |
Why?
|
| Biopsy, Needle | 2 | 2010 | 133 | 0.160 |
Why?
|
| Immunohistochemistry | 3 | 2010 | 899 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 170 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 2 | 2010 | 145 | 0.140 |
Why?
|
| Occupational Exposure | 1 | 2021 | 322 | 0.140 |
Why?
|
| Pandemics | 2 | 2020 | 691 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 165 | 0.140 |
Why?
|
| Hair Removal | 1 | 2018 | 10 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 2 | 2016 | 71 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 161 | 0.130 |
Why?
|
| Adolescent | 3 | 2025 | 6367 | 0.130 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2017 | 8 | 0.130 |
Why?
|
| Laser Therapy | 1 | 2018 | 41 | 0.130 |
Why?
|
| Psoriasis | 1 | 2018 | 59 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 47 | 0.110 |
Why?
|
| Pyridones | 1 | 2015 | 43 | 0.110 |
Why?
|
| 12E7 Antigen | 1 | 2015 | 2 | 0.110 |
Why?
|
| Mucin-1 | 1 | 2015 | 14 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 223 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 53 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1569 | 0.110 |
Why?
|
| Bandages | 1 | 2014 | 17 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 95 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 532 | 0.110 |
Why?
|
| Needles | 1 | 2015 | 63 | 0.110 |
Why?
|
| Physicians | 1 | 2020 | 488 | 0.100 |
Why?
|
| Time Factors | 1 | 2021 | 3777 | 0.100 |
Why?
|
| Temperature | 1 | 2015 | 317 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2015 | 344 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2015 | 747 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2016 | 318 | 0.100 |
Why?
|
| Polyglactin 910 | 1 | 2013 | 5 | 0.100 |
Why?
|
| Dioxanes | 1 | 2013 | 5 | 0.100 |
Why?
|
| Algorithms | 2 | 2010 | 1060 | 0.100 |
Why?
|
| Carcinoma, Verrucous | 1 | 2012 | 3 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 319 | 0.090 |
Why?
|
| Sutures | 1 | 2013 | 40 | 0.090 |
Why?
|
| Polyesters | 1 | 2013 | 45 | 0.090 |
Why?
|
| Quality of Life | 1 | 2020 | 1266 | 0.090 |
Why?
|
| Young Adult | 2 | 2025 | 4882 | 0.080 |
Why?
|
| Prognosis | 1 | 2015 | 1793 | 0.080 |
Why?
|
| Patient Selection | 1 | 2013 | 484 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2025 | 2651 | 0.080 |
Why?
|
| Photography | 2 | 2020 | 43 | 0.080 |
Why?
|
| Eyelid Neoplasms | 1 | 2010 | 9 | 0.080 |
Why?
|
| Itraconazole | 1 | 2010 | 14 | 0.080 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2010 | 9 | 0.080 |
Why?
|
| Prevalence | 1 | 2014 | 1453 | 0.080 |
Why?
|
| Risk Factors | 3 | 2016 | 5475 | 0.070 |
Why?
|
| Inflammation | 1 | 2016 | 1198 | 0.070 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2008 | 5 | 0.070 |
Why?
|
| Recurrence | 1 | 2010 | 665 | 0.070 |
Why?
|
| Plasma Cells | 1 | 2008 | 52 | 0.070 |
Why?
|
| Foreign Bodies | 1 | 2008 | 56 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 41 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2025 | 462 | 0.070 |
Why?
|
| Reagent Strips | 1 | 2007 | 5 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2007 | 92 | 0.060 |
Why?
|
| Skin Pigmentation | 1 | 2007 | 34 | 0.060 |
Why?
|
| Arthrodermataceae | 1 | 2006 | 1 | 0.060 |
Why?
|
| Disease Reservoirs | 1 | 2006 | 10 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 183 | 0.060 |
Why?
|
| United States | 2 | 2014 | 8186 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 182 | 0.060 |
Why?
|
| Candida albicans | 1 | 2006 | 61 | 0.060 |
Why?
|
| Organ Transplantation | 1 | 2006 | 46 | 0.060 |
Why?
|
| Fibrosis | 1 | 2006 | 172 | 0.060 |
Why?
|
| Calcinosis | 1 | 2006 | 84 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2026 | 59 | 0.060 |
Why?
|
| Trifolium | 1 | 2005 | 2 | 0.060 |
Why?
|
| Sanguinaria | 1 | 2005 | 2 | 0.060 |
Why?
|
| Rumex | 1 | 2005 | 2 | 0.060 |
Why?
|
| Ointments | 1 | 2005 | 7 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2026 | 113 | 0.060 |
Why?
|
| Surgical Instruments | 1 | 2005 | 44 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 741 | 0.060 |
Why?
|
| Child | 2 | 2025 | 4651 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2026 | 289 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 208 | 0.050 |
Why?
|
| Complementary Therapies | 1 | 2005 | 63 | 0.050 |
Why?
|
| Radiography | 1 | 2006 | 559 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2026 | 134 | 0.050 |
Why?
|
| Phenotype | 1 | 2008 | 1236 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 200 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2024 | 180 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2024 | 235 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2010 | 3339 | 0.050 |
Why?
|
| Conservative Treatment | 1 | 2022 | 19 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 47 | 0.040 |
Why?
|
| Beauty Culture | 1 | 2021 | 16 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 553 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 46 | 0.040 |
Why?
|
| Educational Status | 1 | 2021 | 279 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 26 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 110 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 49 | 0.040 |
Why?
|
| Video Recording | 1 | 2020 | 140 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 104 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 395 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 106 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2021 | 501 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 133 | 0.040 |
Why?
|
| Skin | 1 | 2020 | 436 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1122 | 0.030 |
Why?
|
| Sodium Bicarbonate | 1 | 2016 | 10 | 0.030 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2016 | 6 | 0.030 |
Why?
|
| Neoplasms | 1 | 2006 | 1377 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 51 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 87 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 379 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 464 | 0.030 |
Why?
|
| Keratin-20 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2010 | 8 | 0.020 |
Why?
|
| Epidermis | 1 | 2010 | 35 | 0.020 |
Why?
|
| Triamcinolone | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2006 | 26 | 0.020 |
Why?
|
| Endarterectomy | 1 | 2005 | 16 | 0.010 |
Why?
|
| Equipment Design | 1 | 2005 | 374 | 0.010 |
Why?
|